How Anti-CGRP Migraine Antibodies Compare in Effectiveness and Side Effects
This review compares the four anti-CGRP monoclonal antibodies (erenumab, fremanezumab, galcanezumab, eptinezumab) for migraine prevention, examining their efficacy, safety profiles, and impact on prophylactic antimigraine medication prescribing patterns.
Quick Facts
What This Study Found
Anti-CGRP monoclonal antibodies represent a paradigm shift in migraine prevention as the first treatments designed specifically for migraine. All four (erenumab, fremanezumab, galcanezumab, eptinezumab) have demonstrated efficacy in clinical trials.
Key Numbers
4 mAbs; 3 target CGRP; 1 targets CGRP receptor; do not cross BBB; hepato-friendly
How They Did This
Narrative review of clinical trial data, prescribing patterns, and safety profiles for anti-CGRP monoclonal antibodies in migraine prevention.
Why This Research Matters
Understanding how these antibodies compare helps patients and clinicians choose the most appropriate option and understand how they fit alongside existing migraine preventive treatments.
The Bigger Picture
Anti-CGRP antibodies validate decades of CGRP research and represent a new era in migraine medicine. Their success is encouraging development of next-generation CGRP-pathway treatments including small molecule oral gepants.
What This Study Doesn't Tell Us
Narrative review. Limited head-to-head comparison data between the four antibodies. Long-term safety data still accumulating. Cost and access remain barriers for many patients.
Questions This Raises
- ?Which anti-CGRP antibody is best for which type of migraine patient?
- ?Does switching between anti-CGRP antibodies benefit non-responders?
- ?What are the long-term safety implications of chronically blocking CGRP?
Trust & Context
- Key Stat:
- 4 antibodies available Erenumab, fremanezumab, galcanezumab, and eptinezumab are all FDA-approved anti-CGRP antibodies for migraine prevention — the first disease-specific preventive treatments for migraine
- Evidence Grade:
- Not applicable (narrative review). Based on high-quality Phase 3 clinical trial data for each antibody.
- Study Age:
- Published 2021. Real-world evidence for anti-CGRP antibodies continues to accumulate with broader clinical experience.
- Original Title:
- The impact of CGRPergic monoclonal antibodies on prophylactic antimigraine therapy and potential adverse events.
- Published In:
- Expert opinion on drug metabolism & toxicology, 17(10), 1223-1235 (2021)
- Authors:
- González-Hernández, Abimael(3), Marichal-Cancino, Bruno A(2), Villalón, Carlos M(2)
- Database ID:
- RPEP-05413
Evidence Hierarchy
Frequently Asked Questions
How do I choose between the four migraine antibodies?
All four have similar efficacy in clinical trials. Differences include delivery method (self-injection vs IV infusion), frequency (monthly vs quarterly), target (CGRP itself vs its receptor), insurance coverage, and individual response. Your neurologist can help determine the best option.
Are anti-CGRP antibodies safe long-term?
Clinical trials and real-world data show they are generally well-tolerated. CGRP has roles beyond migraine (blood vessel dilation, tissue repair), so long-term monitoring continues. Most side effects are mild, mainly injection site reactions.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-05413APA
González-Hernández, Abimael; Marichal-Cancino, Bruno A; Villalón, Carlos M. (2021). The impact of CGRPergic monoclonal antibodies on prophylactic antimigraine therapy and potential adverse events.. Expert opinion on drug metabolism & toxicology, 17(10), 1223-1235. https://doi.org/10.1080/17425255.2021.1982892
MLA
González-Hernández, Abimael, et al. "The impact of CGRPergic monoclonal antibodies on prophylactic antimigraine therapy and potential adverse events.." Expert opinion on drug metabolism & toxicology, 2021. https://doi.org/10.1080/17425255.2021.1982892
RethinkPeptides
RethinkPeptides Research Database. "The impact of CGRPergic monoclonal antibodies on prophylacti..." RPEP-05413. Retrieved from https://rethinkpeptides.com/research/gonzalez-hernandez-2021-the-impact-of-cgrpergic
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.